Lymphedema: Surgical and Medical Therapy.
David W Chang, Jaume Masia, Ramon Garza...
https://pubmed.ncbi.nlm.nih.gov/27556764Actively Recruiting
Led by Fibralign Corporation · Updated on 2025-03-11
60
Participants Needed
2
Research Sites
8 weeks
Total Duration
F
Fibralign Corporation
Lead Sponsor
U
University of Chicago
Collaborating Sponsor
Researchers are evaluating whether adding Fibralign's BioBridge Collagen Matrix devices to standard vascularized lymph node transfer surgery (VLNT) can improve treatment outcomes for upper arm lymphedema caused by breast cancer. This study focuses on patients who have developed secondary lymphedema after breast cancer therapy and aims to measure changes in limb swelling and lymphatic function. The BioBridge is a sterile, implantable surgical mesh made from purified porcine collagen designed to support soft tissue during VLNT. Participants will be randomly assigned to one of two groups: one receiving VLNT surgery with the BioBridge implant and the other receiving VLNT surgery alone. The BioBridge device supports the lymphatic tissues during surgery. Both groups will undergo the surgical procedure followed by a 12-month follow-up period. The study includes monitoring using imaging and quality of life assessments to evaluate the treatment effects. Throughout the study, participants will have measurements of their limb volume taken at the start and 12 months after surgery to assess changes in swelling. Additional evaluations include quality of life surveys (LLIS), bioimpedance spectroscopy (L-Dex), lymphatic function imaging with indocyanine green fluorescence, and tissue histology. Participants are expected to consistently use compression garments and adhere to self-care recommendations. Safety and treatment outcomes will be monitored throughout the study duration, which lasts at least 12 months post-treatment.
CONDITIONS
LymphBridge: Surgical Evaluation for Breast Cancer-Associated Lymphedema (BioBridge)
You may qualify if you...
You will not qualify if you...
Complete this quick 3-step screening to check your eligibility
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 3 weeks post-surgery
Participants undergo vascularized lymph node transplant surgery (VLNT) with or without BioBridge Collagen Matrix implantation, followed by immediate post-operative care.
1 surgery visit and weekly follow-up visits during the first 3 weeks
Duration - 12 months
Participants are monitored for changes in limb volume, quality of life, lymphatic function, and other measures for up to 12 months after surgery.
Visits at baseline and 12 months after treatment
Total: 2 locations
1
The University of Chicago Biological Sciences Division/University of Chicago Medical Center
Chicago, Illinois, United States, 60637
Actively Recruiting
2
MD Anderson
Houston, Texas, United States, 77030
Actively Recruiting
S
Scully Hsu
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
David W Chang, Jaume Masia, Ramon Garza...
https://pubmed.ncbi.nlm.nih.gov/27556764Amanda K Silva, David W Chang
https://pubmed.ncbi.nlm.nih.gov/26846735Danielle H Rochlin, Suzanne Inchauste, Justin Zelones...
https://pubmed.ncbi.nlm.nih.gov/31209884Suzanne Inchauste, Justin Zelones, Danielle Rochlin...
https://pubmed.ncbi.nlm.nih.gov/31228351Rebecca M Garza, Adrian S H Ooi, Joshua Falk...
https://pubmed.ncbi.nlm.nih.gov/30562150